Compare PASG & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | BRNS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 55.9M |
| IPO Year | 2020 | 2021 |
| Metric | PASG | BRNS |
|---|---|---|
| Price | $7.43 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.50 | $4.00 |
| AVG Volume (30 Days) | 30.3K | ★ 31.1K |
| Earning Date | 03-03-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.51 |
| 52 Week High | $20.00 | $2.91 |
| Indicator | PASG | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 40.35 |
| Support Level | $6.71 | $0.56 |
| Resistance Level | $7.72 | $0.76 |
| Average True Range (ATR) | 0.74 | 0.04 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 55.90 | 29.76 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.